I. INTRODUCTION
In March 2008, Andrew Richards was sitting in front of his television when he collapsed suddenly, stating that he felt as if he had been hit with a bolt of lightning. 1 While Richards was indeed felled by electricity, it did not come in the form of lightning; rather, it came in the form of abnormal electrical activity in his brain-in other words, a seizure. 2 Richards, who suffers from depressive symptoms, contends that his seizure was the result of generic substitution, or the process of his pharmacist switching him from a 300 milligram (mg) prescription of Wellbutrin XL, a brand name antidepressant, to a generic version of the drug manufactured by Teva Pharmaceuticals USA. 3 Richards indicated that immediately following the switch he began to experience "jolts and jerks," and that while he and Teva came to a settlement in the civil suit that followed his seizure, he still experiences spasms and other lingering effects associated with the episode. 4 While Richards' "jolts and jerks" may have been warning signs of an impending seizure, in reality warning signs regarding the potential deleterious effects of Teva's generic had existed for over a year prior to his attack. 5 In December 2006, the United States Food and Drug Administration (FDA) approved the first generic versions of Wellbutrin XL. 6 The generic came in two strengths, 150 mg and 300 mg. 7 Within weeks of the release, consumer complaints about diminished effectiveness and negative side effects started pouring in. 8 Initially, the FDA brushed off the complaints, stating its belief that the drugs were equivalent and turning the perceived disparity back on the consumer, indicating that perhaps the consumers' mental illness was the root of the perceived difference, not the actual effectiveness of the drug itself. 9 Though the FDA gave the 300 mg generic its endorsement, skepticism over the drug's "equivalence" did not subside. 10 Alarmed at the sheer number of complaints he was receiving about the generic, People's Pharmacy founder Joe Graedon reached out to independent testing group Consumer Lab and asked it to evaluate the equivalence of the generic to Wellbutrin XL 300 mg. 11 Consumer Lab's results indicated that while the active ingredient in the two drugs was identical, the rate at which the ingredient was released differed tremendously. 12 Within two hours the generic had released 34% of the active ingredient compared to 8% for its brand name counterpart, and within four hours the generic had released almost 50% 6 Angel Reyes III, Generic Wellbutrin XL Antidepressant Recall, REYES L. BLOG (Jul. 02, 2013), http://reyeslaw.com/blog/genericwellbutrin-xl-antidepressant-recall/, archived at http://perma.cc/XY6X-LK7E. 7 Id. 8 Id. original/story?id=17399399, archived at http://perma.cc/BP2H-KW5V. 11 Id. (People's Pharmacy is a popular consumer advocacy group.) 12 Id.
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of the active ingredient versus just 25% for Wellbutrin XL. 13 In effect, the generic functioned more like an immediaterelease drug as opposed to the extended-release product it was advertised to be. 14 Armed with these findings, Graedon confronted the FDA, requesting the generic's bioequivalence testing data. 15 Unfortunately, the FDA could provide no such information; in fact, it informed Graedon that the only bioequivalence testing that generic Wellbutrin XL had been subjected to was on its 150 mg dose-the FDA had merely extrapolated those results to the 300 mg dose and assumed it was also bioequivalent. 16 Subsequent to this admission, the FDA commissioned a bioequivalence study for the 300 mg dose. 17 Results were not encouraging, and indicated that compared to the extended-release Wellbutrin XL 300 mg, the generic did not deliver the active ingredient at the same rate and to the same extent to be considered bioequivalent. 18 On October 3, 2012, approximately five years after the initial complaints started rolling in, the FDA issued a press release stating that Wellbutrin XL 300 mg and Teva's generic version were not therapeutically equivalent. 19 The 13 Id. 14 Id. 15 Id. 16 Bob Pollock, Back in the Headlines-FDA Updates Bioequivalence of Buproprion Extended-Release 300mg Tables,   LACHMAN  CONSULTANTS  (Oct. 11, 2013), http://www.lachmanconsultants.com/back-in-the-headlines-fda-updatesbioequivalence-of-bupropion-extended-release-300mg-tablets.asp, archived at http://perma.cc/THG4-ENVS. 17 Neporent, supra note 10. 18 FDA then retracted its approval of the generic, prompting Teva to voluntarily withdraw the drug from the market. 20 The above example is an extreme case-theoretically, bioequivalence testing before generic drugs enter the market should weed out future similar cases. However, the underlying message is the same: just because drugs feature the same and similar amounts of an active ingredient, it is not necessarily ensured that the drugs will perform equivalently. This Article argues that, in general, and at least as regards psychotropic medications, or medications designed to treat and manage the symptoms of mental health disorders, generic substitution schemes that do not provide for notification or consent of either patients or their doctors are misguided. Part II provides an overview of generic substitution and outlines the different ways that states approach it. Part III discusses scientific issues with generic substitution, exploring the limits of pharmacokinetic studies and the theory of bioequivalence. Part IV examines the efficacy and effectiveness 21 in treating four major categories of mental illness, considers the benefits and detriments of generic substitution for consumers, and discusses treatment and legal issues that are particular to substituting psychotropic medications. Lastly, Part V proffers several solutions for policy change asked pharmaceutical companies producing generic versions of Wellbutrin XL 300mg to carry out bioequivalence studies, has determined that three of the four producers, Actavis, Inc., Mylan, Inc., and Par Pharmaceuticals satisfied bioequivalence standards but one, Watson, did not. by the FDA, and must fulfill several requirements as compared to brand name drugs to obtain approval: 1) they must contain the same active ingredients; 2) they must be identical in strength, dosage, form, and route of administration; 3) they must be manufactured according to FDA standards for branded drugs; 4) they must have the same intended use; 5) they must meet the same batch requirements for identity, strength, purity, and quality; and 6) they must be "bioequivalent." 23 This Article is chiefly concerned with the last requirement. Generic drugs must be "bioequivalent" to their brand name counterparts, meaning that they must show similar bioavailability, defined as "the rate of and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action" 22 under experimental conditions. 24 The concept of bioequivalence is premised on the assumption that if two drugs have similar concentrations and absorption rates in terms of their shared active ingredient, they will be "similarly safe and effective." 25 A generic is considered to be bioequivalent when bioavailability ranges between 80%-125% of the brand-name reference drug with 90% confidence, meaning there is a reasonable certainty that at least 90% of the time the average bioavailability of the generic drug will fall within that range. 26 Further, bioequivalent drugs exist in two types: pharmaceutical equivalents and pharmaceutical alternatives. 27 
B. State Approaches to Generic Substitution
States consider six factors in formulating their generic substitution laws: 1) whether to require pharmacists to utilize the Orange Book (an FDA publication listing/providing guidelines for which generic medications are considered to be bioequivalent); 2) whether to mandate substitution; 3) whether to create a state drug formulary; 4) 24 In bioavailability trials, the FDA is concerned with three things compared to the branded drug: the generic's area under the curve (AUC), Cmax, and Tmax. AUC refers to the mean extent to which a drug's active ingredient is absorbed by the body. Cmax refers to the mean peak concentration that the active ingredient reaches in the body. Tmax refers to the mean time it takes for an active ingredient to reach its Cmax. Scott Gavura, Generic Drugs: Are They Equivalent?, SCIENCE-BASED MEDICINE (Jan. 5, 2012), http://www.sciencebasedmedicine.org/genericdrugs-are-they-equivalent/, archived at http://perma.cc/2SVL-PG93. 27 Vivian, supra note 24. "Pharmaceutical equivalents" are generic drugs as they were defined supra Part II(A). "Pharmaceutical alternatives" are generic drugs that are "formulated with a different salt, ester, or complex." Id. whether to require consent from either the patient or a physician; 5) whether to require that a generic cost less than the brand name version; and 6) whether to recognize narrow therapeutic index (NTI) drugs. 28 A majority of states require pharmacist use of the Orange Book to substitute, but a sizable minority make no reference to the Orange Book in their substitution laws. 29 Concerning mandated substitution, the prevailing approach is for states to permissively allow for substitution at the pharmacist's discretion or in accordance with other regulations, though a minority mandate substitution when a suitable generic is available. 30 Regarding consent, the 28 Id. According to the FDA, NTI drugs are those "containing certain drug substances that are subject to therapeutic drug concentration and pharmacodynamic monitoring," U.S. DEPT quickly the active ingredient in the drugs reaches the absorption site and how much of the active ingredient is absorbed. 34 These studies are based on a single-dose administration of the two drugs in a sample of 24 to 36 volunteers. 35 However, there are several problems with these pharmacokinetic studies. First, bioequivalence studies typically involve sample groups of healthy adult male volunteers who take no other medications, do not smoke, receive a controlled diet, are of average height and weight, and are between 18 and 55 years old. 36 As such, these samples necessarily exclude any investigation of the impact of individual differences in patients that might influence the performance of a medication. 37 This is undesirable because it violates a basic premise of statistics: to extrapolate findings to a population, a sample needs to be representative of that population. A sample such as the one described likely is not representative of all the patient populations to which the results of the pharmacokinetic study will be extrapolated, least of all the patient population with the actual illness or disorder that the drug is designed to treat. 38 Second, the use of a single regulatory acceptance range may be problematic for NTI drugs, or "drugs for which a relatively small change in systemic concentration can lead to marked changes in pharmacodynamics response." 39 In fact, a bioavailability difference as small as 3.5% may yield clinical consequences. 40 Using anticonvulsants as an example, this small difference could result in seizures at the 34 45 Like the example of the homogenous, nonrepresentative sample described above, this procedure raises generalizability concerns. In actual use, few drugs are administered in single doses; instead, most drugs require maintenance of a steady regimen to achieve the desired therapeutic result. 46 The level of drug present in a patient following maintenance of a steady medication regimen is usually substantially higher than the drug levels present with just a single-dose administration, making bioequivalence studies that do not account for this regimen especially problematic. 47 Also, evidence indicates that the differing inactive ingredients present in generic drugs may influence the metabolism, absorption, and distribution of a drug's active ingredient when on a steady maintenance regimen in ways that are not observable following a singledose administration. 48 Lastly, an experiment consisting of a single-dose administration may not properly capture the 41 Id. 42 Blier & Sloan, supra note 25. 43 Meredith, supra note 36, at 2878. 44 Id. 45 Id. at 2879. 46 Id. 47 Id. 48 Id. Although generic drugs are theoretically thought to produce the same results as their brand name counterparts, in reality this may not be true. Though generic and brand name drugs share active ingredients, they may differ in terms of their inactive ingredients or the salt form in which the active ingredient is presented. 50 These inactive ingredients and differing salt forms can impact the performance of generic drugs in a number of ways.
Inactive ingredients can influence the effects of a generic drug in two ways. First, and perhaps most obviously, some individuals may be allergic to the inactive ingredients in generic drug formulations, rendering the generic intolerable. 51 Second, generic and brand name drugs may contain different excipients, or inert substances included in a drug to assist in the process of drug manufacturing, administration, and active ingredient absorption. 52 These excipients may trigger, promote, or partake in chemical or physical interactions with a drug's active ingredient that can jeopardize drug performance and quality. 53 Chemical interactions between active ingredients and excipients may result in drug intolerability, diminished drug safety, and 49 Id. at 2880. 50 Meredith, supra note 36, at 2880. A drug's salt form refers to an "ionisable drug that has been combined with a counter-ion to form a neutral complex." Producing a drug in salt form makes it more chemically stable, allows its pharmacokinetic profile to be manipulated, degradation of a drug's active ingredient. 54 Physical interactions may impact a drug's dissolution, its dosage uniformity, or its ease of administration. 55 Turning next to differing salt forms, the type of salt used to formulate a drug is important, particularly for psychotropic drugs, in that it can influence a drug's physicochemical properties, such as stability, fluidity, and ability to absorb moisture, as well as a drug's kinetics and active ingredient absorption rate. 56 As previously mentioned, drugs containing different salts of the same active substance are called pharmaceutical alternatives 57 and are popular among generic drug makers because they allow for a route around a patent, facilitating earlier entry into the market. 58 However, although pharmaceutical alternatives allow for consumers to gain quicker access to generic drug formulations, there are several potential detriments.
First, the salt form of a drug's active ingredient impacts its aqueous solubility, which can lead to disparate in vivo dissolution characteristics between generics and brand names. 59 This is important because the dissolution characteristics of a drug determine its active ingredient's extent and rate of absorption. 60 Second, differential salt forms of an active ingredient can generate toxicity concerns due to the different conjugate anions or cations used to form the salt compound as well as chemical impurities that may arise during salt formulation. 61 Third, an active ingredient's salt form may influence its tolerability, causing undesirable side effects such as stomach irritation or 54 Id. 55 Polymorphism is important because it impacts equilibrium solubility, a factor in determining the dissolution rate of an active ingredient that can influence bioavailability after oral administration of a medication. 64 Last, the salt form of an active ingredient can influence its physiochemical properties, which affect a drug's formulation as well as its large-scale manufacturing by potentially negatively impacting the uniformity, disintegration, and dissolution rate of solid medications. 65 Two other concerns with generic drug formulations are a drug's water solubility for NTI drugs and the pharmacokinetic profile of modified-release formulations. 66 Regarding the former, water solubility in NTI drugs could lead to concentration differences that can diminish a drug's effectiveness or render it toxic. 67 Concerning the latter, active ingredient concentration profiles in modified-release formulations may differ between generics and brand names during the absorption period of an active ingredient, which might impact a drug's effectiveness despite the fact that the generic drug may technically meet bioequivalence standards. 68 
IV. GENERIC SUBSTITUTION AND MENTAL ILLNESS
Psychotropic medications are drugs targeted at treating and managing the symptoms of mental health disorders. 69 They work by adjusting chemical levels in the brain that 62 Id. at 4. 63 Most clinicians regard medication to be a necessary component in treating bipolar disorder. 79 Historically, the most common medications for bipolar disorders were moodstabilizing drugs containing lithium carbonate. 80 Research has long shown lithium to be a successful treatment for mania, 81 being effective in about 50% of patients and providing approximately a 50% reduction in manic symptoms. 82 However, despite initial treatment success, 74 Id. at 123. 75 Though studies examining the effectiveness of generic lithium to branded drugs are extremely scarce, a handful of studies examining the effectiveness of generic versus branded anticonvulsants in the treatment of bipolar disorders exists due to the significant amount of literature on generic versus branded drugs in the treatment of epilepsy that includes bipolar outcomes; a handful of studies have also examined the comparative effectiveness of other antidepressants and mood stabilizers. Results from a 1979 study found sub-therapeutic levels of lithium in the blood for generic as opposed to branded lithium-based mood stabilizers. 90 Regarding anticonvulsants, one study indicates that depressive symptoms and suicidal thoughts worsened upon switching from branded divalproex to generic valproic acid (though this occurred in a patient with schizophrenia), and several studies suggest an increase in gastrointestinal side effects when taking generic versus branded valproic acid. 91 Several studies have indicated potential deleterious side effects for generic as opposed to branded lamotrigine, with one study observing increases in anxiety, mood swings, dizziness, agitation, headaches, insomnia, and bad taste in the mouth, and another study observing side effects of ataxia, falls, and vertigo. 92 2. Anxiety Disorders Anxiety disorders are characterized by persistent feelings of anxiety, apprehension, and tension, usually centered around perceived future misfortune or danger. 93 These feelings may manifest themselves emotionally 89 97 However, social phobia and specific phobias are more prevalent, affecting an estimated 7-9% of the population every year, though the annual rate of specific phobias is roughly doubled in adolescents. 98 Obsessivecompulsive disorder (OCD) is more rare by comparison, with prevalence rates of 1.2% annually. 99 Medication is commonly used to treat anxiety disorders, with several classes of medications demonstrating efficacy. Benzodiazepines may be used to treat GAD and PD; 100 however, benzodiazepines are not recommended for longterm use given that they do not alleviate symptoms for onethird of people, may impair cognition, exhibit potential for abuse and withdrawal, and, in some studies, show no therapeutic benefit past four to six weeks. 101 Regarding PD, 94 Id. at 235. 95 Id. at 223. 96 Id. at 210. 97 Id. though benzodiazepines have shown therapeutic success, the relapse rate when they are discontinued is quite high, hovering close to 90%. 102 Two types of antidepressants, selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), have shown efficacy for PD; 103 however, SSRIs may cause sexual dysfunction, a side effect that can discourage treatment compliance. 104 This is a concern, especially given that the general medication compliance rate is only about 20% across medications. 105 Concerning OCD, SSRIs benefit approximately 60% of patients, though relapse is common if use of the medication is discontinued. 106 Additionally, multiple classes of antidepressants may help to relieve symptoms of social anxiety, 107 and SSRIs may help to relieve symptoms of PTSD. 108 Although not as extensive as the literature comparing generics and branded drugs for other mental health disorders (though, realistically the literature is thin for all 
Major Depressive Disorder
Major Depressive Disorder ("MDD") is characterized by recurrent depressed mood (including the presence of a major depressive episode), cognitive distortions, and impaired physical functioning to the point where it causes significant distress and impairment and interferes with daily functioning. 111 Common symptoms include feelings of worthlessness, guilt, or indecisiveness; loss of energy; fatigue; diminished interest in once enjoyable activities; psychomotor disturbances; difficulties in thinking and concentrating; significant weight fluctuations; sleep disturbances; and suicidal ideation. 112 MDD is quite prevalent, with 16.2% of individuals estimated to experience the disorder at some point in their lifetime and 6.6% experiencing the disorder within any given year; these percentages may be significantly higher in elderly individuals and in women. 113 of completed suicides being twenty times higher than that of the general population. 114 MDD is often treated with antidepressant medications, which fall into one of four categories: SSRIs, monoamine oxidase inhibitors ("MAOI"), mixed reuptake inhibitors, and tricyclic antidepressants. 115 Research indicates that all four types of antidepressants, at least initially, are equally efficacious, reducing depressive symptoms in about 50% of patients and achieving remission of depressive symptoms in about 25% of patients. 116 However, the drugs differ in terms of their side effects: SSRIs may produce physical agitation, sexual dysfunction, decreased sex drive, insomnia, and upset stomach; MAOIs, in combination with the consumption of foods and drinks containing tyramine, may cause hypertension or even death; and tricyclic antidepressants may produce vision difficulties, difficulties in waste elimination, dry mouth, drowsiness, sexual dysfunction, and weight gain; all of these side effects may lead to reduced levels of medication adherence. 117 Further, despite medication use, relapse rates for depression are high, with 50% of patients relapsing if medication use is discontinued too soon after a major depressive episode. 118 Though branded antidepressants appear to be effective in the treatment of some depressive disorders, generic versions may not perform as well by comparison, as indicated by a handful of studies. 119 produced worsened depression symptoms, decreased blood levels, and increased agitation compared to the branded version; generic mirtazapine (Avanza), desipramine (Norpramin), paroxetine (Paxil), citalopram (Celexa), and fluoxetine (Prozac) are also reported to produce worsened depressive/psychiatric symptoms compared to branded versions. 120 Generic fluoxetine was reported to produce increased anxiety, allergic reactions, relapse of comorbid obsessive-compulsive disorder, and diarrhea; additionally, generic nortiptyline (Aventyl) was reported to produce severe intoxication. 121 Finally, at least one study of generic venlafaxine (Efexor) indicates that its bioavailability does not fall within the acceptable 80% to 125% range of its branded reference drug as required by the FDA. 122
Schizophrenia and Psychotic Disorders
Schizophrenia is a psychotic disorder characterized by a mixture of cognitive, emotional, perceptual, speech, and behavioral disturbances.
Common symptoms include disorganized speech, displaying inappropriate emotions or flat affect, experiencing hallucinations and/or delusions, paranoia, and catatonic movement. 123 Schizophrenia affects about .7% of people at some point in their lives, and the disorder can produce numerous deleterious effects for the individuals who suffer from it, as well as cast a significant financial burden on society; it is estimated that the cost of treating schizophrenics may exceed $60 billion annually. 124 Schizophrenia is a chronic disorder. Even with treatment, full and complete recovery is rare; however, psychotic symptoms tend to subside over time. 125 As such, the treatment focus for those with schizophrenia is often not on curing the disorder but on managing its symptoms. This is https://www.nwpmd.com/Portals/0/Gallery/Articles/Branded%20vs%20G eneric%20Psychotropic%20Medications%20(printer-friendly).pdf. 120 Id. 121 Id. 122 Id. 123 AM. PSYCHIATRIC ASS'N, supra note 73, at 100-01. 124 Id. at 102. 125 Id. at 102-03.
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commonly carried out through the administration of antipsychotic medications. 126 Research regarding medications for schizophrenia reveals some troubling findings.
First, although antipsychotics can help to alleviate symptoms of schizophrenia, they only do so in about 60% of individuals. 127 Second, medication adherence rates for those with schizophrenia are low, with some studies finding that nearly three-quarters of those with schizophrenia stop taking their medications within eighteen months. 128 Third, antipsychotics can produce a host of uncomfortable side effects, such as grogginess, blurred vision, dry mouth, akinesia, and motor abnormalities, which contribute to the aforementioned low medication adherence rate. 129 Though the treatment of schizophrenic individuals with branded medications already presents some difficulties, these difficulties can be compounded when generic medications are utilized. Although some studies suggest generic and branded first-generation antipsychotics perform equivalently, other studies suggest that patients on generic versions may require increased dosage adjustments and may experience exacerbated side effects, such as unprovoked outbursts and drowsiness. 130 Similarly, although a handful of studies have demonstrated the efficacy of generic clozapine in treating schizophrenia, another handful have suggested that individuals receiving generic clozapine experience either worsened symptoms or relapse at greater rates than do individuals on branded versions. 131 The substitution of generic versions of psychotropic medications provides at least one potential benefit to consumers.
Although inactive ingredients in generic medications may influence the way that drugs are absorbed into the body, this risk is more severe for drugs with narrow therapeutic indexes; the risks of differential effectiveness of generic in comparison to branded drugs is less pronounced for psychotropic drugs with high therapeutic indexes. 134 To this end, the cost savings provided by using generic psychotropics may be well worth the small risk of differential effectiveness between generics and brand names for drugs with high therapeutic indexes. For some drugs, the costs savings can be substantial; for example, the branded amphetamine Adderall® 135 costs approximately $84 for a 30-day supply, whereas generics Dexedrine® and dexamphetamine cost over $50 less for the same thirty-day supply. 136 Similarly, a 60% increase in the dispensing of generic antidepressants decreased medication costs by 9%. 137 Despite the economic benefit for consumers stemming from the substitution of generic drugs for branded versions, consumers may also experience myriad detriments. First, as discussed above, generic psychotropics, at least for some individuals, may not be as effective at treating their mental illness as brand name psychotropics. 139 Second, the substitution of generic psychotropics, at least under schemes without the requirement of notification or consent of the consumer or doctor, may infringe on individuals' autonomy in making their own medical decisions. 140 Third, generic substitution tends not to reflect consumer preferences. In a 2009 survey of 1047 people, researchers found that while a majority of Americans support the idea of generic substitution, 10% thought that generics caused a greater number of side effects compared to branded drugs, one-third of individuals expressed some degree of discomfort with generic substitution, and only 38% expressed a personal preference for generics, a result that is contradictory given that a majority reported favoring the idea. 141 This suggests that Americans may believe that generic drugs are right for others, but not for themselves. This effect is less pronounced in younger, more educated consumers, but is also strongly influenced by the seriousness of the illness being considered, with individuals expressing a greater preference for brand-name drugs for more serious illnesses. 142 C. Why Should We Care?
Though there may be both benefits and detriments to the substitution of generic psychotropics, the detriments outweigh the potential benefits for three reasons. 
Mental Health Disorders as Chronic Disorders
Of the four aforementioned mental disorders, schizophrenia, MDD, and bipolar are viewed as chronic conditions.
Roughly 75% of individuals afflicted with schizophrenia will experience alternating periods of relapse and remission during the course of their lifetime, with full recovery constrained to under one-fifth of cases. 144 Regarding bipolar disorders, recent research suggests that bipolar manifests itself in a chronic course "characterized by periods of residual symptoms, emotional dysregulation, sleep and circadian rhythm disturbances, cognitive impairment, and increased risk for psychiatric and medical comorbidity between mood episodes." 145 Considering major depressive disorder, research suggests that it is an episodic yet persistent condition, with about three-quarters of individuals who reached clinical levels of depression reporting that they had experienced multiple depressive episodes. 146 Given that major depressive disorder, bipolar, and schizophrenia are viewed as chronic disorders and that medication plays a key role in the treatment of all three, care should be taken to provide individuals with these disorders the best and most effective medication. 147 As indicated previously, for some individuals, generic psychotropic drugs will not fit this bill. 148 
Medication Adherence
Given that medication is a key part of treatment for schizophrenia, major depressive disorder, and bipolar, medication adherence is essential. Despite its importance, many individuals with mental illness do not comply with their medication regimens; some estimates indicate that as many as half of individuals on medication for psychiatric illness are not fully adherent. 149 This is problematic, as non-adherence may lead to poor treatment outcomes such as relapse, weakened treatment benefits, and hospitalization. 150 A number of factors may influence non-adherence. Some non-adherence is related to characteristics of individuals, such as a lack of insight into their disease, forgetfulness, the severity of the illness, experiencing depressive and psychotic symptoms, low cognitive ability, and substance dependency. 151 Some non-adherence stems from the therapeutic alliance, with individuals who perceive their doctor as helpful, trustworthy, and collaborative more likely to be adherent than those who do not perceive their doctor in those ways. 152 Still other non-adherence may be influenced by external factors, such as stigma, cost, and availability. 153 However, most important to this Article is that some non-adherence stems from factors having to do with the medications themselves.
Research indicates that individuals are less likely to be adherent when they experience adverse side effects from a medication, such as weight gain or sexual dysfunction. 154 Research also indicates that individuals are more likely to be adherent to a brand name as opposed to a generic medication. 155 Additionally, medication switching influences adherenceindividuals who notice repeated changes to the shape, color, or packaging of their medications are less likely to be adherent to a medication regimen than those who do not experience such changes. 156 This influence may be magnified for individuals with psychotic symptoms, who may perceive such changes to be indicative of maltreatment. 157 Given the many reasons individuals may not be adherent to their medication, including brand name medications, it seems foolhardy to compound these reasons by introducing the possible detrimental effects of switching individuals from a brand name to a generic without their consent.
Patient Autonomy: The Right to Medical Decision Making
In addition to presenting scientific and treatment concerns, generic substitution may present a legal concern 151 Id. 152 Id. at 339. 153 Id. at 338. 154 Id. 155 Id. 156 Correll & Carbon, supra note 119. 157 Id. In Cruzan, a case in which a vegetative woman's right to refuse life support was at issue, the Court held that competent individuals have a right to refuse medical treatment if they so choose. 163 Extending these holdings to generic substitution, taking prescription medication is a private medical decision, much like abortion or contraception. Additionally, much like Cruzan, competent individuals should have the ability to refuse medical treatment, meaning that individuals should have an opportunity to dissent to the substitution of a generic in place of a brand name medication-this is not possible under generic substitution schemes that require no notification or consent. As such, the right of individuals to confer with their doctor and choose which medications they would like to be prescribed should be a fundamental right fundamental right and that while Texas had some compelling reasons for restricting abortions, such as protecting health and potential life, a blanket prohibition was broad enough that it exceeded the bounds of those compelling interests. Id. at 162-67. The Court held similarly in a lesser-recognized companion case to Roe, Doe v. Bolton. Doe v. Bolton, 410 U.S. 179 (1973) . Doe involved plaintiff Mary Doe (pseudonym), a married woman who desired the ability to obtain a legal abortion in her home state of Georgia. Id. at 185. At the time, Georgia law prohibited abortion except in cases where it was necessary to save the life of the mother, where the pregnancy was the result of rape, or where the child was at risk of being born with a serious defect or disability; additionally, the statute contained a host of procedural restrictions. Id While awaiting trial, Riggins complained that he was having auditory hallucinations and was having trouble sleeping, and was prescribed antipsychotics. Id. at 129. Riggins moved for a determination of his competence to stand trial and was found competent; upon this finding, Riggins argued that he wanted to assert an insanity defense against trial, and it was a violation of his Due Process rights to medicate him as it (1) would not allow him to show his natural state at trial and (2) the drug's negative impacts on him would impede his ability to contribute to his defense. Id In applying these holdings to the issue of generic substitution, the Supreme Court has made it clear that, at least regarding prisoners with mental illness, forcible treatment and medication is to be considered a measure of last resort. This is interesting in light of the Court's holding in Turner v. Safley, which indicated that, given reduced individual liberty and security concerns in prisons, prisons should be given deference in the restriction of prisoners' rights provided that such restrictions were "reasonably related to legitimate penological interests." 174 If prisoners, whom the Court has recognized as being subject to liberty and rights restrictions not imposed upon everyday citizens, are not subject to medication against their will except under a strict set of circumstances, why then would it be fair or constitutional to allow individuals who are mentally ill to have a generic drug substituted for a brand name drug when their will regarding such substitution is not known, as in generic substitution schemes that do not involve a consumer's or doctor's notification or consent?
Third, generic substitution may constitute a battery under tort law. Most jurisdictions provide for battery actions for patients who did not consent to a medical treatment. 175 A majority of jurisdictions allow for patients to recover when they consent to a medical treatment but the physician deliberately deviates from the patient's wishes; additionally, some jurisdictions hold that physicians will be held liable if they provide medical treatment to which a patient has not given express or implied consent. 176 An argument can be made that this conception of medical battery should apply to generic substitution, at least in the abstract. First, although pharmacists are not physicians, they play a role in the treatment process as the gatekeepers of medications. Second, under permissive substitution schemes, pharmacists can exercise their discretion in choosing to fill a patient's prescriptions with a generic, effectively allowing them to make a treatment 174 decision for a patient. Third, under a scheme that is both permissive and does not require patient or doctor notification, a pharmacist might ostensibly make a treatment decision but never need to inform the patient, thus never providing the patient an opportunity to render either express or implied consent to the pharmacist. Given the fact that generic substitution may allow for pharmacists to facilitate administration of a treatment without obtaining consent, a pharmacist who decides to substitute a generic drug that has differential effectiveness or detrimental side effects compared to a brand name drug should be liable for battery, at least from a theoretical perspective. All three of the above issues illustrate potential concerns that may arise when considering the impact of generic substitution on patients' rights to have a voice in their medical treatment. The Supreme Court has long recognized the privacy of individuals' medical decisions with their doctors and the right of individuals not to be medicated without their consent. Ostensibly, tort law should allow for patient recovery if consumers are provided with medication for which they did not consent. Although not all generic substitution schemes are subject to these problems, schemes involving no notification arguably are, and as such should be viewed as a violation of a consumer's right to autonomy in medical decision making.
Seemingly Overlooked Problems: Criminal Culpability and Pharmacist Liability
Another legal reason for concern regarding generic substitution stems from the seemingly overlooked problems of criminal culpability and pharmacist liability. Considering criminal culpability, so-called "psychotropic defenses" are gaining popularity, as evidenced in both news reports 177 is predicated on controversial research, which indicates that some psychotropic drugs may spur an adverse reaction in the form of violent behavior. 179 Although controversial, adverse reactions to psychotropic drugs should diminish culpability, at least theoretically. Under the American system of justice, punishment is justified under two main theories: utilitarianism and retributivism. 180 Utilitarianism is predicated on the idea that punishment can function as a social good, helping to protect society and offenders through general and specific deterrence, rehabilitation, and isolation. 181 Retributivism, on the other hand, has its foundation in morality-for justice to be served, a wrongdoer must be punished for his actions. 182 Applying the principles of punishment to the psychotropic defenses, at least in the context of substitution that requires no notification, under utilitarian rationales individuals' behavior cannot be deterred if it is not a function of their personality but rather a byproduct of a reaction to a medication people did not know that they were taking. Additionally, punishment of an individual claiming a psychotropic defense would not serve the purposes of rehabilitation and isolation-proper rehabilitation in this instance would not be punishment but rather would be switching the individual back to a medication regimen that was tolerable and did not produce the adverse effects that precipitated a crime, thus rendering no need for isolation. Similarly, under a retributivist rationale in which moral wrongdoing is punished, it is hard to see how justice might be served by punishing individuals whose volition may have 318 INDIANA HEALTH LAW REVIEW Vol. 12:1 been impaired by a drug they did not know they were taking, negating any intention to do wrong. Another controversial defense that generic substitution may engender is involuntary intoxication. Under common law, a defense of involuntary intoxication may arise when a defendant ingests a substance that induces an adverse reaction that triggers criminal activity, and that substance was ingested due to the negligence or malpractice of a physician or the malevolent intentions of another person. 183 Though an involuntary intoxication defense usually stems from the ingestion of alcohol or an illegal drug, some courts recognize the defense when the criminal action is precipitated by a wrongly administered medication or by a medication administered correctly but that produced an unexpected effect. 184 Extended to the example of generic substitution, a medication may be interpreted to be wrongly administered when consumers thought they were taking a brand name medication but in reality were taking a generic. This can also happen when consumers experience adverse reactions to a medication that they did not expect based on their understanding of the brand name medication that they thought they were taking.
A second unanticipated concern is pharmacist liability. Considering that the ability for pharmacists to substitute is granted by the state and states have an incentive to keep drug costs down, it might seem intuitive that pharmacists would be shielded from liability in the event that a generic produced differential effects than associated with a brand name drug. In reality, this is not the case. In a survey of its closed pharmacist liability cases in the United States during a ten-year window from January 1, 2002 to December 31, 2011, the insurance provider CNA/Healthcare Providers Service Organization (HPSO) found that 1.9% of its wrong drug dispensation cases involved the failure of a pharmacist to verify the equivalency of a generic prior to substitution and that 3% of its medication mismanagement cases involved the failure of a pharmacist to inform a 183 WELNER, supra note 171, at 635-37. 184 Id. consumer of the change to a generic form of a drug. 185 Although not constituting a substantial portion of CNA/HPSO closed pharmacist liability cases, these cases indicate that pharmacists do not enjoy absolute immunity from lawsuits and that they should not be surprised if an injured individual takes action against them for the substitution of a generic drug.
Limitation of Remedies for Persons Injured by Generic Psychotropics and Competitor Liability
A final legal cause for concern regarding generic psychotropics is the lack of a path to recovery for individuals injured by them. 186 189 The two individuals sought recovery under a theory of failure to warn, claiming that the generic version of Reglan that they were provided did not provide warning that taking the drug for longer could cause tardive dyskinesia. 190 In 2004, subsequent to Respondents' development of tardive dyskinesia, branded Reglan's manufacturer requested approval from the FDA to change the drug's warning label to indicate that treatment should not exceed twelve weeks in length. 191 Ruling on the basis of preemption, the Court held that respondents could not recover under state tort law because for PLIVA to be in compliance with state tort law, it would have to be out of compliance with federal regulations that required generic medications to utilize the same warning labels as their branded counterparts. 192 In essence, PLIVA did not fail to warn-rather, it was unable to warn. 193 Similarly, Mutual Pharmaceutical Co., Inc. v. Bartlett arose when Respondent received a prescription for brand name Clinoril to treat shoulder pain, but instead was dispensed a generic version. 194 Shortly after receiving the generic, Respondent, a resident of New Hampshire, became afflicted with an acute case of toxic epidermal necrolysis that disfigured, disabled, and nearly blinded her. 195 At the time, Clinoril did not have a warning label apprising consumers of the possibility of toxic epidermal necrolysis. 196 Respondent filed suit under theories of design-defect and failure to warn, claiming that New Hampshire law required drug manufacturers to ensure the safety of the design of their product, which could be established by way of adequate warning about a drug's potential hazardous effects. 197 Relying on its holding in Mensing, the Court again held that federal regulations requiring generic drugs to employ the same warning labels as their branded counterparts preempted stated law, and that Mutual could not have changed its warning labels to address the 2015 ARE BIOEQUIVALENTS REALLY EQUAL? 321 possibility of toxic epidermal necrolysis and still be in compliance with federal regulations. 198 Mensing and Bartlett effectively barred injured consumers from asserting a failure to warn claim against a generic drug manufacturer as the generic manufacturer is reliant upon branded drug manufacturers in terms of what can be put on a warning label; this bar significantly limits the paths to recovery for individuals harmed by generics. 199 However, a potential -though controversial -route around the preemption issue could be to sue the branded company when a consumer is injured by a generic drug under competitor liability. 200 Applied in this context, competitor liability asserts that brand name manufacturers should be held liable for adverse reactions to generic versions of the drug under theories of negligent misrepresentation and fraud, arguing that due to federal labeling regulations, it is "eminently foreseeable" that a physician may prescribe a generic version of a medication while relying on the warning label of a branded medication. 201 Though this is a very small minority approach, 202 it is indicative of savvy lawyers potentially raising the issue in the future as a way to navigate around Mensing and Bartlett when clients are injured by psychotropic medications.
